Latest Drug for AMD, Beyond The Reach Of Common Man ( Lucentis is the new drug which is claim...)

Latest Drug for AMD, Beyond The Reach Of Common Man

Lucentis is the new drug which is claimed to be very effective in treating age-related macular degeneration (AMD) It is not been approved by the FDA //but is thought to replace another proven and cost effective drug. Lucentis is manufactured by Genentech and is already called the wonder drug. AMD is a chronic eye disease affecting 1.7 million Americans and a leading cause of blindness in the country.

Dr. Philip Rosenfeld, a macular-degeneration specialist in Miami said that the drug can be replaced by Avastin which has a very similar molecular structure. About 10,000 people were administered Avastin which has given very good results. Lucentis can't repair the irreversible retina damage but prevents the blood-vessel leakage in the back of the eye that causes damage. The patients suffer from distorted, wavy vision, and eventually a gap in the center of their vision. In the trails session itself Lucentis was found to have improved the patient’s eyesight by at least three lines on a vision chart.

The only disadvantage is that Lucentis will cost more than 100 times as much as the temporary fix. A dose of Avastin for the eye costs about $13 whereas Lucentis cost up to $3000 for a single dose. Doctors too will most likely turn to the more expensive drug. The problem is that Avastin has not been subjected to rigorous testing for AMD, and it would take Genentech years and huge amount of money to do those tests with Avastin. Megan Pace, spokeswoman for the company said that the cost factor would be taken care of by the company and hence patients need not worry about it.

Page: 1
Related medicine news :

1. Latest device for identifying Melanomas
2. Latest discovery on Autism
3. Latest device for cardiac revival under test
4. Latest technique for asthma treatment
5. Latest drug shows promise in multiple myeloma
6. Latest Findings On The Deadly Disease - SARS
7. Latest Tumor Classification More Informative
8. The Latest Preventative Treatment Option for Prostate Cancer
9. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
10. A Latest Study Links Fish To Stroke
11. Enhanced Gene Therapy Outcomes Following Latest Revolution And Refinement

Post Your Comments:

(Date:12/4/2009)... North American Seminars Inc....host continuing medical education courses at their...acility to showcase its operation and capabilities...overall costs to educate their physical therapy an...45 facilities hosted over 250 live training events...

(Date:12/4/2009)... , OAKLAND, Calif., Dec. 4 H... among children who have been vaccinated against c... in the December issue of the Pediatric Infectiou...of its kind, used electronic health records to ide...he varicella (chicken pox) vaccine from 2002 to 20...

(Date:12/3/2009)... , SOUTHBRIDGE, Mass., Dec. 3 ...roval to treat its first patients, Harrington Hosp...eing patients immediately," said Diane Becquart, D...The approval was granted today by the Massachusett...nd quality review of the facility. ,, The open...

(Date:12/3/2009)... , CHICAGO, Dec. 3 /PRNewswire-USNewswire/ -... today that the United States District Court for t...minary approval of the previously disclosed $350 m...n lawsuit against UnitedHealth Group. ,, The ac...ate of New York and Missouri State Medical Associa...

(Date:12/3/2009)...ormin outperforms widely used sulfonylureas, but e... , THURSDAY, Dec. 3 (HealthDay News) -- A cla... type 2 diabetes is associated with a higher risk ...t metformin, researchers say. , , Sulfonylureas... less well than metformin in a study of oral anti-...

Breaking Medicine News(10 mins):Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 2 Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 3 Health News:North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program 4 Health News:Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 2 Health News:Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children 3 Health News:Cancer Center at Harrington to Begin Seeing Patients 2 Health News:Cancer Center at Harrington to Begin Seeing Patients 3 Health News:Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 2 Health News:Diabetes Drugs Go Head-to-Head in Study 2 Health News:Diabetes Drugs Go Head-to-Head in Study 3

[1] North American Seminars Inc. Opens Its 2010 Physical Therapy Continuing Medical Education Course Sponsorship Program [0] Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children [0] Cancer Center at Harrington to Begin Seeing Patients [0] Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court [0] Diabetes Drugs Go Head-to-Head in Study

...ic bingo to fulfill the unmet needs of ...SACRAMENTO, Calif., May 13 The California Charity...dvocate for the use of,traditional and technologic...e include Disabled Sports USA Far West,Capitol Fre...

...omprehensive Wellness Products and ...3 Veria -- a growing natural,health and wellness ...etwork), local wellness centers, and a lifestyle-f...apeutic massage,services, with 420 clinics open na...

...dward G.,Rendell today signed three bills into law... drug repository program,that allows pharmacies, u...y, to redispense unused cancer drugs to cancer pat...e,drug expires no sooner than six months after the...

...enue increase 12.0 percent demonstrating ...ting for first time since separation; strategic in...ts, - Management updates financial guidance based ...g for the first time since the spin-off of the,fun...

...NDS INC.,(Amex: TOF ) today announced its results...., Net sales for the thirteen weeks ended March 2...h net sales of $4.85 million for the thirteen,week...iod., For the thirteen weeks ended March 29, 2008...

...ts.com,Inc. (Nasdaq: DIET ), leveraging the power... lifestyle solutions to everyone, today announced,...venues for the first quarter of 2008 were $8.8 mil...irst quarter of,2008, compared to $(1.3) million, ...

Charities Form Alliance to Preserve and Improve Charity Bingo Veria Announces Acquisition of Massage Envy Ltd.PA Governor Rendell Signs 3 Bills Into Law Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year TOFUTTI Announces First Quarter Results eDiets.com(R) Announces Q1 2008 Results

(Date:12/3/2009)...PRNewswire-FirstCall/ -- Ted Karkus, Chairman and ...www.quigleyco.com announced today that the Compan...s to develop prescription pharmaceutical and OTC p...nterests to focus primarily on the OTC/Personal Ca...ted to its Cold-EEZE® and Kids-EEZE® bra...

(Date:12/3/2009)...3 Wound Management T...pidly growing provider of specialty medical produc...ndustry Representative Association (HIRA) to serve...g representative to market the company,s core Cell...A will market and sell Wound Management Technologi...

(Date:12/3/2009)...ire/ -- Apnex Medical, Inc., a private medical dev...ond round of private equity financing totaling $14...nical study and develop a second generation of its...eat obstructive sleep apnea (OSA). ,, Participa...w Enterprise Associates (NEA), Polaris Venture Par...

Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2 Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3 Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2 Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3 Apnex Medical, Inc. Raises Additional $14 Million 2 Apnex Medical, Inc. Raises Additional $14 Million 3 Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference 14588 1 Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference 14588 2 Jellyfish Protein Extends Neuroprotective Tentacles at Neuroscience Conference 14588 3 Mimotopes Launches Online Peptide Superstore 14585 1 Mimotopes Launches Online Peptide Superstore 14585 2 Mimotopes Launches Online Peptide Superstore 14585 3 Qteros Employees Planting Special Trees in Celebration of International Day of Climate Action October 24 2009 14582 1 Qteros Employees Planting Special Trees in Celebration of International Day of Climate Action October 24 2009 14582 2 Qteros Employees Planting Special Trees in Celebration of International Day of Climate Action October 24 2009 14582 3

[0] Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution [0] Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up [0] Apnex Medical, Inc. Raises Additional $14 Million

...lment in May 2009; Reinforces Lilly,s commitment t... , , INDIANAPOLIS, May 21 Eli Lilly and Company...lling patients this month in two separate but iden... previously referred to as LY2062430, an anti-amyl... a potential treatment to delay the progression of...

...Application (NDA) to the U.S. Food and Drug Admini...nippon Sumitomo Pharma Co., Ltd., (DSP) announced ...ical trial for lurasidone, which is under clinical...ts with schizophrenia. In this six-week, double-b...ay was significantly more effective than placebo f...

Other Medicine Technology:Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 2 Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 3 Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 4 Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 5 Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia 2 Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia 3 Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia 4 Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia 5

Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia

Seattle Small Joint Arthroscopy Cup Currette

...he Small Fragment Plate and Screw System provides ... on angular deformities; particularly the opening ... hallux valgus correction). The Small Fragment Pla... with a removable caddy that houses the plates, sc...

Teardrop punch, Right

LactoSorb® No-Profile Screw and Washer

Medicine Products:

Seattle Small Joint Arthroscopy Cup Currette Small Fragment Plate and Screw System Teardrop punch, Right LactoSorb® No-Profile Screw and Washer

( Lucentis is the new drug which is claim...)Latest Drug for AMD, Beyond The Reach Of Common Man,Health